U.S. FDA Grants Orphan Drug Exclusivity for Xywav® Oral Solution for Idiopathic hypersomnia (IH) in Adults
The United States Food and Drug Administration (FDA) has granted Orphan Drug Exclusivity (ODE) to Jazz Pharmaceuticals plc's Xywav® (calcium, magnesium, potassium, and sodium oxybates) oral solution f ...